Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

Serum albumin, ferritin, folate, vitamin B12, and 25-hydroxyvitamin D levels remained stable relative to baseline, with no significant differences between groups.

Source: Postoperative complications. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Cohort study.

Cohort study

Examines exposures and outcomes over time within a defined group.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

In this retrospective cohort study, 26 patients with mild obesity and 76 matched patients with higher BMI underwent MBS between 2013 and 2020.

Source: Abstract.

After surgery, patients were managed within a structured multidisciplinary program involving metabolic and bariatric surgeons, endocrinologists, dietitians, rehabilitation physicians, and specialized metabolic and bariatric nurses.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Metabolic and bariatric surgery in mild obesity: mid-term outcomes and safety in an Asian population

Cohort study · Frontiers in Endocrinology · 2026

Original publication title

Metabolic and bariatric surgery in mild obesity: mid-term outcomes and safety in an Asian population

Wanying Zhong; Lijun Chen; Yuanhao Huang; Dalong Zhu; Wenjuan Tang; Yuqin Ouyang; Xuehui Chu; Wenhuan Feng

Copyright © 2026 Zhong, Chen, Huang, Zhu, Tang, Ouyang, Chu and Feng.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

In Asian patients, MBS appears safe and provides durable metabolic benefits across BMI categories. Despite losing less weight, those with mild obesity achieved similar cardiometabolic improvements and were more likely to reach a normal BMI. These findings are preliminary. Future research should prioritize large, multicenter studies focusing on the BMI 27.5 to 30 kg/m² subgroup without advanced metabolic disease, randomized trials comparing surgery with current pharmacotherapies, and long-term studies tracking hard cardiovascular endpoints.

An extract from the source publication. Read it in context.

At a glance

Abstract: What objectives does the paper state?

To evaluate the mid-term (≥3 years) efficacy and safety of MBS in Asian patients with mild obesity, compared with those with BMI ≥MIhe kg/m².

Source: Objective

Abstract: What methods does the paper describe?

In this retrospective cohort study, 26 patients with mild obesity and 76 matched patients with higher BMI underwent MBS between 2013 and 2020. Outcomes included percent total weight loss (%TWL), metabolic control, remission of obesity-related comorbidities, and postoperative complications. The primary composite endpoint was defined as glycated hemoglobin <6.5%, low-density lipoprotein cholesterol <2.6 mmol/L, systolic blood pressure <130 mmHg, and homeostasis model assessment of insulin resistance <2.5 mmol/L, μU/mL.

Source: Methods

Abstract: Results

At a mean follow-up of approximately 5 years, the mild obesity group achieved lower %TWL than the higher-BMI group (approximately 20% vs 26%, P < 0.05). Despite this, the rate of achieving the composite metabolic endpoint was comparable (30.7% vs 27.6%, P = 0.76). Both groups demonstrated sustained improvements in glycemic control, lipid profile, blood pressure, and insulin resistance. Remission of type 2 diabetes, hypertension, hyperuricemia, and metabolic-associated fatty liver disease increased significantly in both groups (all P < 0.05).

Notably, a substantially greater proportion of patients in the obesity group achieved normalization of body weight (BMI <24 kg/m²). Complication rates were low and comparable.

Source: Results

Abstract: Conclusion

In Asian patients, MBS appears safe and provides durable metabolic benefits across BMI categories. Despite losing less weight, those with mild obesity achieved similar cardiometabolic improvements and were more likely to reach a normal BMI. These findings are preliminary. Future research should prioritize large, multicenter studies focusing on the BMI 27.5 to 30 kg/m² subgroup without advanced metabolic disease, randomized trials comparing surgery with current pharmacotherapies, and long-term studies tracking hard cardiovascular endpoints.

Source: Conclusion
Authors’ abstract

Background

Metabolic and bariatric surgery (MBS) is an established treatment for severe obesity, but its role in Asian patients with mild obesity (body mass index [BMI] 27.5-32.5 kg/m²) remains controversial due to limited mid-term evidence. This study evaluated the ≥3-year outcomes of MBS in this population compared with patients with BMI ≥32.5 kg/m².

Objective

To evaluate the mid-term (≥3 years) efficacy and safety of MBS in Asian patients with mild obesity, compared with those with BMI ≥MIhe kg/m².

Methods

In this retrospective cohort study, 26 patients with mild obesity and 76 matched patients with higher BMI underwent MBS between 2013 and 2020. Outcomes included percent total weight loss (%TWL), metabolic control, remission of obesity-related comorbidities, and postoperative complications. The primary composite endpoint was defined as glycated hemoglobin <6.5%, low-density lipoprotein cholesterol <2.6 mmol/L, systolic blood pressure <130 mmHg, and homeostasis model assessment of insulin resistance <2.5 mmol/L, μU/mL.

Results

At a mean follow-up of approximately 5 years, the mild obesity group achieved lower %TWL than the higher-BMI group (approximately 20% vs 26%, P < 0.05). Despite this, the rate of achieving the composite metabolic endpoint was comparable (30.7% vs 27.6%, P = 0.76). Both groups demonstrated sustained improvements in glycemic control, lipid profile, blood pressure, and insulin resistance. Remission of type 2 diabetes, hypertension, hyperuricemia, and metabolic-associated fatty liver disease increased significantly in both groups (all P < 0.05).

Notably, a substantially greater proportion of patients in the obesity group achieved normalization of body weight (BMI <24 kg/m²). Complication rates were low and comparable.

Conclusion

In Asian patients, MBS appears safe and provides durable metabolic benefits across BMI categories. Despite losing less weight, those with mild obesity achieved similar cardiometabolic improvements and were more likely to reach a normal BMI. These findings are preliminary. Future research should prioritize large, multicenter studies focusing on the BMI 27.5 to 30 kg/m² subgroup without advanced metabolic disease, randomized trials comparing surgery with current pharmacotherapies, and long-term studies tracking hard cardiovascular endpoints.

Publication and source details

Original title: Metabolic and bariatric surgery in mild obesity: mid-term outcomes and safety in an Asian population

Wanying Zhong; Lijun Chen; Yuanhao Huang; Dalong Zhu; Wenjuan Tang; Yuqin Ouyang; Xuehui Chu; Wenhuan Feng

Frontiers in Endocrinology · 2026

* Correspondence: Wenhuan Feng, fengwh501@163.com; Xuehui Chu, chuxuehui@njglyy.com

†These authors have contributed equally to this work

Copyright © 2026 Zhong, Chen, Huang, Zhu, Tang, Ouyang, Chu and Feng.2026Zhong, Chen, Huang, Zhu, Tang, Ouyang, Chu and Fenghttps://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.The author(s) declared that financial support was received for this work and/or its publication. This study and its publication were supported by the following funding sources: the National Science and Technology Major Project for Noncommunicable Chronic Diseases (2023ZD0508105, 2024ZD0531701); the 2025 Nanjing Drum Tower Hospital Clinical Research Special Fund Project (Grant No. 2025-LCYJ-MS-07); the Key R&D Program of Jiangsu Province, China (BE2022666); the National Key Research and Development Program of China (2021YFC2501600 and 2022YFC2505306); the Special Fund for Health Science and Technology Development of Nanjing City (YKK23072); the National Natural Science Foundation of China (82030026 and 82270883); the Natural Science Foundation of Jiangsu Province (BK20201115); the Major Programs in Clinical Medicine of Nanjing City; and the Key Medical Discipline Cultivation Unit of Jiangsu Province (JSDW202201). The article processing charges for this journal were covered by the authors.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-10T22:29:22.352370+00:00

DOI: 10.3389/fendo.2026.1828283 · PMC13229718